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Background: Morquio A (MPS IVA) is a rare disease characterised by a deficiency of N-acetylgalactosamine-6
sulfatase (GALNS) and presenting with short stature, abnormal gait, cervical spine instability and shortened lifespan.
Purpose: To prepare a systematic review of the prevalence of Morquio A in multiple countries and suggest
recommendations for reporting rare diseases.
Methods: Medline, Medline In-Process, Medline Daily Update, Embase, Cochrane Database of Systematic Reviews,
Cochrane Central Register of Controlled Trials, Database of Abstracts of Reviews of Effects, Health Technology
Assessment Database and PROSPERO were searched from inception to October 2013 to identify relevant information
on the epidemiology of Morquio A. Forty Patient Organisation Representatives (POR) and Key Opinion Leaders (KOL)
across 24 countries were contacted for data. Observational studies were included and case reports were excluded.
Searches were performed without date or language restriction. Two researchers independently screened and extracted
data. Quality of study reporting was assessed using a checklist adapted from STROBE (STrengthening the Reporting of
OBservational studies in Epidemiology). Point or birth prevalence was stratified according to diagnostic method and
discussed narratively.
Results: In total 9,074 records were retrieved from searching and 25 studies were included for data extraction. Twenty
out of 40 KOL and POR responded (50%) and 9 provided data (23%). Point prevalence of Morquio A was 1 per 926,000
in Australia, 1 per 1,872,000 in Malaysia and 1 per 599,000 in UK and Morquio (unclassified) was 1 per 323, 000 in
Denmark. Birth prevalence of Morquio A (using recommended diagnostic methods) ranged from 1 per 71,000 in
UAE to 1 per 500,000 in Japan. All results were compromised by poor study reporting and internal validity.
Conclusions: The review highlighted that there is a misunderstanding of the definitions for prevalence and incidence
in the field; that studies were poorly reported (diagnostic methods and patient characteristics) and that no suitable
quality assessment tool exists. Overestimation and underestimation of prevalence data can occur. Bespoke reporting
guidelines and a quality assessment tool specifically for prevalence of rare diseases are recommended.
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The Mucopolysaccharidoses (MPS) are a group of inher-
ited metabolic disorders caused by a deficiency or mal-
functioning of lysosomal enzymes which are needed to
break down complex carbohydrates known as mucopoly-
saccharides or glycosaminoglycans (GAGs). Accumulation
of GAGs causes a cascade of events leading to the progres-
sive damage of cells, tissue and organs. Morquio disease or
Mucopolysaccharidosis Type IV (MPS IV) belongs to this
group and has two sub-types, A and B. Type A is also
known as Morquio A, GALNS deficiency, Galactosamine-
6-sulfatase deficiency, N-acetylgalactosamine-6-sulfate sul-
fatase deficiency or more simply MPS IVA, while type B
is known as Morquio B, beta-galactosidase deficiency or
MPS IVB. They are often grouped together with other
rare diseases under the umbrella of lysosomal storage
disorders (LSDs). The Orpha number for Morquio A is
ORPHA309297. Morquio A is characterised by a defi-
ciency of N-acetylgalactosamine-6 sulfatase (GALNS)
[1], which results in a build-up of chondroitin-6-sulfate
(C6S) and keratan sulfate (KS) in many tissues and
organs. This build up results in multi-systemic clinical
impairments including musculoskeletal abnormalities,
short stature, pulmonary and cardiac dysfunction, hearing
loss and corneal clouding [2]. A recent report by Lavery
and Hendriksz (2014) reported the average age of death
for a Morquio A patient in the UK to be 25 years with
respiratory failure as the main cause of death (63%) [3].
Morquio B results from a deficiency of beta-galactosidase
activity and usually patients have a more attenuated
phenotype compared to Morquio A [4,5]. It is important
to mention that in many cases beta-galactosidase deficiency
leads to accumulation of GM1 ganglioside, causing the
neurodegenerative disease GM1 gangliosidosis (with early
infantile, juvenile of adult phenotypes). To date, the full
spectrum of Morquio B has not been well documented,
with reports of patients with intermediate phenotype
between Morquio B and GM1 gangliosidosis [6,7]. The
clinical symptoms for Morquio were first described in
1929 [8], but it was not until the 1960s that elevated levels
of GAGs in the urine of patients were discovered and the
term MPS IV was used (reviewed in Hendriksz et al. 2013
[9]). In 1976, Singh et al. found that the enzyme N-
acetylgalactosamine-6 sulfatase was deficient in Morquio
A and in the following year Morquio B identified as a sep-
arate entity [9].
Where Morquio A or B is clinically suspected, the rec-
ommended means of obtaining a diagnosis is by measuring
the enzymatic activity of GALNS or beta-galactosidase re-
spectively in either fibroblast or leukocyte samples [9-11].
Measurement of enzyme activity in dried blood spots
(DBS) can be useful [12], but it is recommended that low
activities should be confirmed in leucocytes as activity
could be impaired by transportation and/or storage insub-optimal conditions [8]. Additional biochemical inves-
tigation and/or genetic analysis should be performed to
rule out potential false positives incurred by different
diseases such as multiple sulfatase deficiency (MSD) or
mucolipidosis II or III (ML II/III) where low GALNS ac-
tivity may be present [10]. Other diagnostic methods,
namely urinary KS identification by thin-layer chroma-
tography or electrophoresis, or tandem mass spectrometry
(TMS), or KS measurement in plasma or DBS can be used
as screening methods. When KS detection is used as
screening, the likelihood of false negatives becomes higher
as patients age. One of the main sources of KS is cartilage,
thus when bone growth plates close in patients reaching
puberty the rate of KS accumulation slows and urinary
excretion is substantially reduced and may even disappear
[13]. Measurement of KS is not specific to Morquio A as
patients with Morquio B and MSD also excrete increased
amounts of KS [5,14]. Elevated KS has been reported in
other MPS disorders and mucolipidoses [12]. KS can also
be elevated in other LSDs such as Fucosidosis and GM1
gangliosidosis [15]. All diagnostics methods should be
clearly reported and should include a description of how
the samples were stored.
Molecular analysis can confirm biochemical analyses
and more than 180 different mutations have been identi-
fied for the GALNS gene, but in isolation it can incon-
clusive or complicate the diagnostic process as common
mutations have only been identified for specific ethnic
sub-populations [9] and variants of unknown significance
may be found. Genetic analysis of cases already diagnosed
is useful to identify new mutations and also to identify car-
riers, being helpful for genetic counselling and prenatal
diagnosis [10]. Treatment measures were largely palliative
and focussed on alleviating organ specific complications
[15] until specific enzyme replacement therapy (ERT)
became approved [16].
Morquio A and B are both autosomal recessive inher-
ited conditions which affect males and females equally
and in most cases, both parents of an affected child are
asymptomatic carriers of the disease. Morquio A is a
rare condition and existing data on prevalence are scarce
and variable. Reported estimates range from 1 per 76, 320
in Northern Ireland [17] to 1 per 641,178 in Western
Australia [18]. Morquio B is even more rare and as a con-
sequence, data on prevalence are even more scarce. It is
important to consider factors such as consanguinity, mi-
gration and founders effect as they can have a profound
effect on prevalence of genetic disorders. Up to date and
accurate prevalence data are required to inform policy
makers and indicate a need for development and direction
of treatment. Currently it is unclear what the exact preva-
lence of Morquio A is and there are different methods for
calculating prevalence and reporting data from rare dis-
eases. The aim of the paper was to conduct a systematic
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tries. In addition we discuss the challenges and limitations
of completing a systematic review in the field of rare
diseases.
Methods
This systematic review was carried out in a transparent and
reproducible nature as recommended by the Cochrane
Collaboration [19] and the Centre for Reviews and
Dissemination [20] and in accordance with the PRISMA
statement [21].
Inclusion criteria
We included observational studies that reported the
prevalence or incidence of MPS IV, MPS IVA, Morquio A
and over-arching terms such as Lysosomal storage dis-
orders (including synonyms) from the following countries
(without further limitations): Australia, Brazil, Canada,
Colombia, Denmark, France, Germany, Italy, Japan,
Malaysia, Mexico, Netherlands, Poland, Portugal, Qatar,
Russia, Saudi Arabia, Spain, South Korea, Taiwan, Turkey,
United Arab Emirates (UAE), United Kingdom (UK) and
United States of America (USA). These countries were
chosen on the basis of current known cases of Morquio A.
Case series (from 1970) were included in the absence of
prevalence or incidence data (if they reported newly diag-
nosed cases and a time period for data collection). Where
Morquio or MPS IV was reported and no distinction was
made between A and B, we categorised these data as
Morquio (unclassified). Case reports were not included.
Literature searches
Searches were carried out from inception to October 2013
in Medline; Medline In-Process & Other Non-Indexed
Citations; Medline Daily Update; Embase; Cochrane
Database of Systematic Reviews (CDSR); Cochrane Cen-
tral Register of Controlled Trials (CENTRAL); Database
of Abstracts of Reviews of Effects (DARE); Health Tech-
nology Assessment Database (HTA); and PROSPERO
(International Prospective Register of Systematic Reviews)
to identify relevant information on the epidemiology
and prevalence of Morquio A. Only studies conducted in
humans were sought. Searches were not limited by date
(except for prior stated study design criteria), language or
publication status (unpublished or published). An example
of the search strategy is documented in Additional file 1.
The main Embase strategy for each set of searches was
independently peer reviewed by a second Information
Specialist, using the CADTH checklist [22].
Supplementary searches were undertaken to identify
completed and ongoing trials, on NIH ClinicalTrials.gov
(http://www.clinicaltrials.gov); MetaRegister of Controlled
Trials (mRCT); (http://www.controlled-trials.com) and
WHO International Clinical Trials Registry Platform(ICTRP) (http://www.who.int/ictrp/en), from inception to
October 2013. All identified references were imported into
Endnote X4 software and duplicates were removed. The
bibliographies of identified research and review articles
were checked for additional relevant studies. Initial
searches based on specific terms for Morquio A failed
to retrieve some known studies; therefore broader terms
for mucopolysaccharidoses and lysosomal storage disor-
ders were employed.
Contacting registries, patient organisations and key
opinion leaders
For each included country, key opinion leaders and patient
organisations were contacted where possible. Each person
contacted was requested to provide information on: preva-
lence/incidence/birth rate/number of cases (including units
of measure), definition of prevalence/incidence/birth rate/
number of cases or method for calculation, time period
over which data were gathered, geographical location,
method/criteria for diagnosis of to identify relevant infor-
mation on the epidemiology and prevalence of Morquio A,
% male, age, weight, height, ethnicity and any additional
comments.
Methods of study selection, quality assessment and data
extraction
Titles and abstracts were independently screened by two
reviewers; full papers obtained for agreed relevant studies
were again independently examined in detail to deter-
mine whether they met the inclusion criteria. All studies
excluded based on reading the full paper were docu-
mented along with the reasons for exclusion. Quality of
study reporting was independently assessed by two re-
viewers using a checklist we adapted from the STROBE
(STrengthening the Reporting of OBservational studies
in Epidemiology) statement for the reporting observa-
tional studies specifically for the review [23]. A guide to
assessing the quality of study reporting (also developed
for this review) is included in Additional file 2. The follow-
ing information was extracted from studies: author, year,
country, type of Morquio, study data collection period,
study design, study setting, number lost to follow-up,
diagnosis, method for genotyping, predefined inclusion
and/or exclusion criteria, description of the participants
included in the study, genotype, ethnic background,
evidence of consanguinity, study aim and prevalence/
incidence/birth rate/number of cases (including units
of measure), definition of prevalence/incidence/birth rate/
number of cases or method for calculation and reported
study limitations. Data were extracted into specially de-
signed extraction sheets in Microsoft Excel 2007 by one
reviewer and checked by a second. Any discrepancies
between reviewers were resolved through discussion or
the intervention of a third reviewer.
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To summarise data and compare the prevalence of
Morquio A across countries, data were grouped according
to the definition of point prevalence or birth prevalence.
Given that these are inherited conditions, people cannot
acquire them nor be cured, consequently “incidence”
(number of new cases in a given time period) is a less
helpful construct. If incidence was reported we analysed
the definition to determine whether or not it was equiva-
lent to a definition for point prevalence or birth prevalence.
Those that were identical were included under a new pre-
valence definition. Only postnatal diagnoses or prenatal
diagnoses that resulted in a live birth were included. Def-
inition for birth prevalence = (the number of cases with a
birth defect in a defined area and time period × 10, 000) ÷
(the number of live births in that area and time period.
Definition for point prevalence = (the number of cases of
a defect of any age in a defined area on a given date) ÷
(entire population in a defined area on a given date) [24].
Studies which provided the numbers of cases diagnosed
with Morquio A were converted to birth prevalence
(if there was a time frame and birth statistics for that
given time and country). Estimates of point prevalence of
Morquio A (and numbers of living patients), were calcu-
lated for studies which used recommended diagnostic
techniques using the following calculation; birth pre-
valence × (MPS IVA life expectancy/population life ex-
pectancy). Population numbers for countries and region
were taken from https://www.cia.gov/library/publications/
the-world-factbook/fields/2102.html#138 and Wikipedia
respectively. These estimates assumed that the mean life
expectancy of Morquio A patients was 25.3 years [3] to
account for patients who may have died during the study
period. The results were discussed narratively.
Results
In total, 9, 074 records were retrieved from database
searches and 25 were included for data extraction.
Figure 1 summarises the flow of records through the
search and screening process. Of the 61 full records that
were screened, 36 did not meet the inclusion criteria and
were excluded. Seven were duplicates; the reasons for the
remaining 29 exclusions are listed in Additional file 3.
Twenty out of 40 key opinion leaders (KOL) and patient
organisations (POR) responded to our communications
(50%) of which 9 provided data (23%). Two KOL’s pro-
vided additional data not included in their publications
[25,26]. Analysis of the included data indicated that 4
KOL and 11 published studies provided data for cases or
prenatal diagnoses which could not be used to calculate
prevalence and were excluded (summarised in Additional
file 4). In total we included 5 sets of prevalence data from
KOL and PO, and 13 published studies containing preva-
lence data from database searches. Of the 24 countries ofinterest, we found data for 13, namely, Australia, Brazil,
Canada, Colombia, Denmark, Germany, Japan, Malaysia,
Netherlands, Saudi Arabia, Taiwan, UAE, and UK.Study characteristics
Study characteristics were summarised in Table 1 and
patient characteristics in Additional file 5. All studies
were reported to be case series or epidemiological studies
of 1 to 34 year duration. The diagnostic methods em-
ployed by the different reports were not described in
detail. Eight reported the use of enzyme analyses for all
patients [27-34] and 6 reported that this was performed in
leukocytes or fibroblasts [27-29,32-34]. Two studies re-
ported methods for genotyping [25,34].
None of the included studies from literature search-
ing specifically aimed to investigate Morquio A, but
were concerned with investigating prevalence in more
than one disease e.g. MPSs or LSDs. The majority of
studies reported data for Morquio A and Morquio B
[17,18,28,29,31,32,35-38], 4 studies reported unspecified
Morquio [33,34,39,40] and 4 studies reported data for
Morquio A only [25,27,31,41]. Few studies reported
details of patient characteristics: 4 studies reported gen-
der [27-29,36], 5 reported age [29,31,33,35,36], 1 reported
genotype [25]; 7 reported ethnicity or geographical
background [25,27,29,32,33,36,39] and 2 studies reported
consanguinity [25,34].Quality of study reporting
To assess the quality of reporting of the published studies
we adapted the STROBE guidelines by selecting recom-
mendations most relevant to rare diseases (see Additional
file 2) [23]. The quality of reporting was summarised
in Table 2. None of the studies were judged to have a
high quality of reporting; 7 studies were judged as
medium [18,25,30-32,37,39], and 6 were judged to be
low [17,33,34,38,40,41]. No studies (0%) provided ad-
equate descriptions of the included participants; 10/13
(77%) studies provided adequate descriptions of study
design; 3/13 (23%) studies adequately described the eligibil-
ity criteria of the participants; 11/13 (85%) studies provided
sufficient information to determine that the study popula-
tion was representative of the target population and 7/13
(54%) studies adequately described the outcomes.
Additional file 6 lists all identified study limitations
reported by the included studies. Important points raised
were lack of central registration system, referral centres
or neonatal screening, lack of patient characteristics,
movement of patients out of the country of interest dur-
ing long study periods, lack of study reporting adhering
to guidelines, difficult diagnosis, clinical heterogeneity or
severity and underdiagnoses due to mild cases and lack
of trained staff.
Figure 1 Flow diagram of included studies.
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Only 1 published study and 3 KOL reported point pre-
valence data (Table 3). Point prevalence of Morquio
(unclassified) in Denmark was 1 per 323, 000 as of 31st
December 2007 [33]. In Australia, in 2013, point preva-
lence of Morquio A was 1 in 926,000 [27] while in
Malaysia it was 1 per 1,872,000 [28]. In the UK, based on
figures from 2011 census, point prevalence for Morquio A
was 1 per 599,000 [29]. These results were based on stud-
ies with a low or ungraded quality of reporting. In UK and
Denmark studies it was reported that the prevalence was
influenced by the presence of the disease in Pakistani
immigrants.
Birth prevalence was summarised in Table 4 (Morquio
A), Table 5 (Morquio unclassified). The results were stra-
tified according to whether or not the recommendeddiagnostic enzymatic analysis in leukocytes or fibro-
blasts was used. Other factors which may influence the
reliability of the data were also summarised (evidence of
consanguinity, evidence of ethnicity founder effect and
study period).
Six studies from Australia, Canada, Germany, Japan
and UAE presented data for Morquio A birth prevalence
and used the recommended enzymatic analysis. For
these studies prevalence ranged from 1 per 71,000 [25]
to 1 per 500, 000 [35]. The reliability of these figures
was compromised by unclear reporting of whether or
not the cases were born during the study and all had
long study periods (15-24 yrs). In addition, in Germany
it was reported that there was a founder effect from
Turkish immigrants (22% of the patients) [32] and in
UAE, consanguinity may have influenced the prevalence
Table 1 Characteristics of included studies reporting prevalence data




Study setting/Data source Criteria for diagnosis Methods for genotyping
KOL Australia [27] Case series NR 33 National Referral Laboratory and QLD laboratory
Australian Bureau of Statistics
Enzyme assay performed on fibroblasts







Public 16 National Referral Laboratory, Dept. Chemical
Pathology, Women’s and Children’s Hospital
(Adelaide) and the Division of Chemical Pathology,






NR 27 Genetic and hospital files: Princess Margaret
Hospital for Children & King Edward Memorial
Hospital for Women, Perth. Medical files: Disability
Services Commission of W. Australia, Perth.
Laboratory records: Dept. Chemical Pathology,
Women’s and Children’s Hospital, Adelaide. The
Dept. Clinical Biochemistry, Princess Margaret
Hospital for Children, Perth. Membership list of
the Society for MPS Diseases (W. Australian Parents
Support Group). Records of the Birth Defects
Registry of W. Australia.
Diagnosis was confirmed by one
dimensional electrophoresis of urinary
GAG and/or by enzyme assay on
leucocytes or fibroblasts.
NR
KOL Brazil [36] Retrospective
case series





Case series NR 28 Diagnoses made at the Biochemical Diseases
Laboratory, Children’s Hospital, Vancouver. Birth
records from the British Columbia Vital Statistics
Agency.
Specific enzyme assays. NR
Lowry 1971 Canada
(BC) [40]
NR NR 16 Multiple sources of ascertainment: discharge
diagnoses from all inpatients in the hospitals in
BC, children’s outpatient’s clinics, public health
units, residential institutions for the mentally
retarded, the physician’s notice of birth, private




Case series Public 34 The Biochemical Diseases Laboratory (BDL) of
the Department of Pathology, B.C.’s Children’s


























Public 9 Record histories: Genetics Laboratory The Victoria
Hospital, Bogota (Cundinamarca), District
Department of Health, El Salvador, of Ubaté
(Cundinamarca), Genetics Outpatient Clinic, and
patient care area of municipalities (Fúquene,
Simijaca Sutatausa, Susa, Carmen de Carupa,
Cucunubá, Lenguazaque, Guachetá Tausa, Boyaca.
Medical records of the Institute of Human
Genetics at the Pontificia Universidad Javeriana,
Bogota, and the databases of patient records
affiliates to ACOPEL (Colombian Association of
Patients with Lysosomsal Disease). Data for live
births were obtained from the Dept. National
Statistics (DANE).
All clinical assessment was by a
specialist in clinical genetics. The
diagnosis was confirmed by
electrophoresis GAG in urine test
determining enzyme levels in leukocytes
performed in specialized laboratories or
by both techniques widely used in







NR 30 In Denmark; until 2003: the Kennedy Institute in
Glostrup and the Dept. Clinical Genetics at
Rigshospitalet, Copenhagen. Today all diagnostics
is performed at Rigshospitalet.
Analysis of GAGs in urine (heparan-,
dermatan- and keratansulphate) in
persons with a clinically suspected
MPS. When urinary levels of GAGs are
increased, the findings of a low or
deficient enzyme level in lymphocytes








NR 15 The identification of affected patients was attained
using the following ascertainment sources: 1.
Membership list of the German Society for MPS.
2. Patient records from (a) Children’s Hospital,
University of Mainz (b) Dept. Pediatrics, and
University of Hamburg. 3. Laboratory records from
(a) University of Gottingen, (b) University of Munster,
(c) University of Heidelberg, (d) University of
Greifswald, (e) University of Mainz.
In all cases the diagnosis was
confirmed by enzyme assay in serum,
leukocytes and/or fibroblasts.
NR
POR Japan [35] NR NR 20 Japanese MPS Society The diagnoses have been performed
generally based on enzyme analysis.
NR
KOL Malaysia [28] Retrospective
case series
NR 1 Data collected from 4 major hospitals in Malaysia
with clinical genetics service (Hospital Kuala Lumpur,
Hospital Pulau Pinang, Hospital Universiti Sains
Malaysia, University Malaya Medical Centre).





Case series NR 26 The records from the laboratories of the clinical
genetic centres involved in the post- and prenatal
diagnosis of LSD. The main referral laboratories
for the diagnosis of LSD, viz. the clinical genetics
centres of Leiden, Nijmegen and Rotterdam,
contributed 95% of all cases. Additional information
was obtained from the other contributing laboratories.
Cases were enzymatically confirmed,




















Table 1 Characteristics of included studies reporting prevalence data (Continued)
Moammar 2010
Saudi Arabia (EP) [34]
Retrospective
case series
NR 25 Main medical centre in Dhahran, Eastern
Province of Saudi Arabia. Birth Statistics from
Mortality and Morbidity Reports 1983–2008,
Epidemiology Services Unit, Preventive Medicine
Services Division, Saudi Aramco Medical Services
Organization (SAMSO).
Diagnosis of all glycogen and lysosomal
storage disorders was confirmed by
enzyme activity estimation on cultured
skin fibroblasts, liver biopsy, or leukocytes.




Lin 2009 Taiwan [38] Retrospective
case series
Public 21 Data obtained from: (1) Membership list of Taiwan
MPS Society (2) Medical records from (a) Mackay
Memorial Hospital, Taipei, Taiwan (b) Taipei
Veterans General Hospital, Taipei, Taiwan (c) China
Medical University Hospital, Taichung, Taiwan (d)
Kaohsiung Medical University Chung-Ho Memorial
Hospital, Kaohsiung, Taiwan (e) Kaohsiung Veterans
General Hospital, Kaohsiung, Taiwan (f) National
Cheng Kung University Hospital, Tainan, Taiwan
(g) Buddhist Tzu Chi General Hospital, Hualien,
Taiwan (h) Chang Gung Children’s Hospital, Taoyuan,
Taiwan (i) Tri-Service General Hospital, Taipei,
Taiwan (j) National Taiwan University Hospital,
Taipei, Taiwan (3) Laboratory records from
Department of Medical Research, Mackay Memorial
Hospital, Taipei, Taiwan (4) Records of Taiwan
Foundation for Rare Disorders (5) Records of
Bureau of Health Promotion, Department of Health,
R.O.C. (Taiwan).
The diagnosis of all patients was
confirmed by two-dimensional
electrophoresis of urinary GAGs and/or
enzyme assay in serum, leukocytes
and/or fibroblasts.
NR
Al-Jasmi 2010 UAE [25] Case series NR 15 Two metabolic referral centres in UAE, Latifa
Hospital (Dubai), Tawam Hospital (Abu Dhabi).
Clinical presentation and biochemical
analysis.
Direct genomic sequencing
of GALNS gene for MPS IVA.
Nelson 1997 UK (NI) [17] Case series NR 27 These were hospital consultants’ records;
records of the screening laboratory for urinary
mucopolysaccharides; the diagnostic indices of
the Dept. Medical Genetics; The Queens University
of Belfast, The Royal Victoria Hospital, Belfast and
The Royal Belfast Hospital for Sick Children; and
files of the Hospital activity analysis (Nelson 1986).
Urinary GAGs were examined by 2D
electrophoresis. In all cases where the
patient was alive at the time of the
study, the diagnosis was confirmed by
he appropriate enzyme assay.
NR
KOL UK [29] Case series NR 38 Whole of the UK including devolved nations
Wales, Scotland and Northern Ireland. Data
provided by KOL.
Diagnosis will have been made by
laboratory on urine GAGS and enzyme
analysis. Some will also have
mutational analysis.
NR
Abbreviations: BC British Columbia, B&C Boyacá and Cundinamarca, DNA Deoxyribonucleic acid, EP Eastern Province, GAG Glycosaminoglycan, GALNS N-acetylgalactosamine-6 sulfatase, IEM Inborn errors of metabolism,
KOL Key opinion leader, LSD Lysosomal storage disorder, MPS Mucopolysaccharidoses, NI Northen Ireland, NR Not recorded, PCR Polymerase chain reaction, POR Patient organisation representative, UAE United Arab



















Table 2 Quality of reporting of included studies
First author and publication year Country 1. Was there an
adequate description
of study design?
2. Was there an
adequate description
of eligibility criteria?
3. Is the study population
representative of the
target population?
4. Is there an
adequate description
of outcomes?





Meikle 1999 [31] Australia Yes Yes Yes No No Medium
Lowry 1990 [41] Canada (BC) No Unclear Yes No No Low
Lowry 1971 [40] Canada (BC) No Unclear Unclear No No Low
Applegarth 2000 [30] Canada (BC) Yes Yes Yes Yes No Medium
Nelson 2003 [18] Australia (W) Yes No Yes Yes No Medium
Gomez 2012 [39] Colombia (B&C) Yes No Yes Yes No Medium
Malm 2008 [33] Denmark No Unclear Yes Yes No Low
Baehner 2005 [32] Germany Yes Yes Yes No No Medium
Poorthuis 1999 [37] Netherlands Yes Unclear Yes Yes No Medium
Moammar 2010 [34] Saudi Arabia Yes Unclear No Yes No Low
Lin 2009 [38] Taiwan Yes Unclear Yes No No Low
Al-Jasmi 2010 [25] UAE Yes Unclear Yes Yes No Medium
Nelson 1997 [17] UK (NI) Yes Unclear Yes No No Low
Abbreviations: BC British Columbia, B&C Boyacá and Cundinamarca, NI Northern Ireland, UAE United Arab Emirates, UK United Kingdom.



















Table 3 Summary of point prevalence data






Point in time Recommended
Enzymatic analysisǂ
Quality
Australia KOL [27] MPS IVA 1 in 926,000* 0.0108* NR NR Y 30th June 2013 Y ungraded
Denmark [33] MPS IV (unclassified) 1 per 323, 000* 0.031* NR Y Y 31st Dec 2007 Y low
Malaysia KOL [28] MPS IVA 1 per 1,872,000 0.005* NR NR Y 30th June 2013 Y ungraded
UK KOL [29] MPS IVA 1 per 599,000* 0.0167* NR Y Y Mid-2010 Y ungraded
Abbreviations: KOL Key Opinion Leader, NR Not recorded, UK United Kingdom, Y Yes.



















Table 4 Summary of birth prevalence for Morquio A
Birth
prevalence



















Australia KOL [27] 1 per 253,000 0.04* NR NR Y 24 (1980–2013) 0-45 Y Y Yǂ ungraded
Germany [32] 1 per 263,000* 0.0380* NR Y Y 15 (1980–1995) NR NR Y Yǂ medium
UAE (Emirates) [25] 1 per 71, 000 0.14* Y NR N 15 (1995–2010) NR Y Y Yǂ medium
Australia [31] 1 per 201, 000 0.0497* NR NR Y 17 (1980–1996) 0-19 NƗ Y Y medium
Canada (BC) [30] 1 per 207,000* 0.048* NR NR N 24 (1972–1996) NR NR Y Y medium
Japan (POR) [35] 1 per 500,000 0.02* NR NR unclear 20 (1991–2011) NR NR Y Y ungraded
Australia (W) [18] 1 per 641, 000 0.0156* NR NR N 27 (1969–1996) NR Y Y unclear medium
Netherlands [37] 1 per 459, 000* 0.022* NR NR Y 26 (1970–1996) NR Y Y unclear medium
Taiwan [38] 1 per 304,000 0.033* NR NR Y 20 (1984–2004) NR NR Y unclear low
UK (NI) [17] 1 per 76, 000 0.13* NR NR N 27 (1958–1985) NR NR Y unclear low
Brazil (KOL) [36] 1 per 1,179,000* 0.009* NR NR Y 9 (2004–2013) 1-6 Y Y NR ungraded
Canada (BC) [41] 1 per 216, 000 0.046* NR NR N 34 (1952–1986) NR NR Y NR low
Abbreviations: BC British Columbia, KOL Key Opinion Leader, POR Patient organisation representative, N No, NI Northern Ireland, NR Not recorded, UAE United Arab Emirates, UK United Kingdom, W West, Y Yes. *Calculated by



















Table 5 Summary of birth prevalence for Morquio (unclassified)
Birth
prevalence
























1 per 28, 000* 0.362* Y N N 25 (1983–2008) NR Y Y Yǂ low
Denmark [33] 1 per 208, 000* 0.048* N Y y 29 (1975–2004) NR NR Y Yǂ low
Colombia
(B&C) [39]
1 per 147, 000* 0.068* N N N 9 (1998–2007) NR Y Y unclear medium
Canada (BC) [40] 1 per 303,000 0.033* N N N 16 (1952–1968) NR NR NR low
Abbreviations: BC British Colombia, B&C Boyacá and Cundinamarca, KOL Key Opinion Leader, N No, NR Not recorded, UK United Kingdom, Y Yes.
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http://www.ojrd.com/content/9/1/173data as birth prevalence was reported for emirates and
not non-emirates (who constitute 80% of the population
of UAE) [25]. The Emirate population are described as
ethnically diverse and included over 70 distinct tribes
which had few inter-tribal marriages. Six studies from
Australia, Brazil, Canada, Netherlands, Taiwan and UK
(NI) presented data for Morquio A birth prevalence but
it was unclear if they had used the recommended en-
zymatic analysis. For these studies prevalence ranged
from 1 per 76,000 [17] to 1 per 1,179,000 [36]. The reli-
ability of these figures was compromised by unclear
reporting of whether or not the cases were born during
the study [29,38,41] and all except Brazil (9 years) [36]
had long study periods (15–34 years). Nelson et al. re-
ported birth prevalence in Northern Ireland, a small and
isolated region and therefore arguably not representative
of the UK [17]. In addition, the text reports the inclusion
of mild cases of Morquio A [17].
Table 5 presents birth prevalence for Morquio (unclas-
sified). Two studies in Denmark and Saudi Arabia used
the recommended diagnostic method [33,34]. The preva-
lence of these countries ranged from 1 per 28, 000 to 1
per 208, 000. The limitations of Denmark were discussed
above. The study of Saudi Arabia investigated Morquio
(unclassified) specifically in the eastern province and
used the medical records from an oil company; therefore
it was not representative of the country. In addition, the
result for Saudi Arabia was further compromised by evi-
dence of consanguinity (patients were frequently siblings
and all had consanguineous parents), poor quality of
study reporting and the study was carried out over a
long period (25 years) [34]. Two studies from Colombia
and Canada presented data for Morquio (unclassified)
birth prevalence but it was unclear if they had used the
recommended enzymatic analysis [36,38-40]. For these
studies prevalence ranged from 1 per 147, 000 to 1 per
303, 000. The reliability of Canada was discussed above.
The data for Colombia were not representative of theFigure 2 Birth prevalence of Morquio A and Morquio unclassified.whole country [39]. All birth prevalence data are illus-
trated in Figure 2.
Estimated point prevalance and number of cases alive
from reported birth prevalence
To try and overcome the limitations that restricted life
span imposes on calculations of prevalence, particularly
performed on data collected over many years we tried to
estimate point prevalence (and numbers of people alive
with MPS Morquio A). Estimations were performed for
the studies with the recommended diagnosis techniques
only and the results are summarised in Table 6. Esti-
mated point prevalence range from 1 per 1,664,000 in
Japan (estimated 76 cases) to 1 per 217,000 in UAE (esti-
mated 25 cases). The estimates are averaged over the
study period and are still compromised by the limits dis-
cussed above.
Discussion
Point prevalence was reported by the following countries:
Australia (1 per 926,000) [27]; Denmark (unclassified
Morquio = 1 per 323, 000) [33]; Malaysia (1 per 1,872,000)
[28] and UK (1 per 599, 000) [29]. Birth prevalence was
reported by the following countries: Australia, Brazil,
Canada, Germany, Japan, Netherlands, Saudi Arabia,
Taiwan, UAE and UK. For Morquio A birth prevalence
ranged from 1 per 71, 000 [25] to 1 per 500, 000 [35] for
studies with recommended diagnostic methods. For all
unclassified Morquio, birth prevalence ranged from 1 per
28, 000 [34] to 1 per 208, 000 [33] for studies with recom-
mended diagnostic methods. No data were found for
prevalence of Morquio A in France, Italy, Mexico, Poland,
Portugal, Qatar, Spain, South Korea, Turkey or United
States of America (USA).
All results for prevalence were compromised by poor
study reporting and internal validity (flaws in the design
or conduct of the study) as detailed in the quality and
results sections. Contacting the KOL and POR resulted









Australia KOL [27] 0.04 1 per 810,000 0.0123 27
Germany [32] 0.038 1 per 835,000 0.0120 97
UAE (Emirates) [25] 0.14 1 per 217,000 0.0460 25
Australia [31] 0.0497 1 per 652,000 0.0153 34
Canada (BC) [30] 0.048 1 per 668,000 0.0150 7
Japan (POR) [35] 0.02 1 per 1,664,000 0.0060 76
Abbreviations: BC British Columbia, KOL Key Opinion Leader, POR Patient organisation representative, NI Northern Ireland, UAE United Arab Emirates, UK United
Kingdom, W West. *Calculated by authors from Tables 4 and 5; #average point prevalence for study period.
Estimated MPS IVA patients alive = MPSIVA point prevalence × population.
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http://www.ojrd.com/content/9/1/173in a poor response rate; given time more information
may have been forthcoming. A systematic review proved
an effective method of obtaining information on preva-
lence of Morquio A. To our knowledge this is the first
systematic review of its kind, investigating the preva-
lence of Morquio A in multiple countries.
Challenges of performing a systematic review of
prevalence of a rare disease
Few systematic reviews exist on the prevalence of rare
conditions. For Morquio A, there was limited informa-
tion on prevalence. When attempting to retrieve studies
difficulties may arise if Morquio A is included within a
broader report investigating lysosomal storage disorders,
metabolic disorders, MPS diseases or inborn errors. In
practical terms it can be challenging to identify and
screen studies for records of Morquio A or MPS IVA if
it is only one of many conditions. In our current re-
search we noted that Morquio A may not be referred to
in the title or abstract, but may appear only in a table.
Therefore screening on the title and abstract alone for
specific diseases would lead to the loss of important doc-
uments and therefore it is important to be aware of cat-
egories under which rare diseases may be grouped.
Assessment of study quality is an essential part of a
systematic review. For this review we adapted the
STROBE checklist [23]. As judged by our assessment, no
studies were reported well. In general there was a lack of
reporting for the method of diagnosis; type of Morquio
(i.e. Type A or B) and no studies adequately described
the characteristics of study participants. The lack of
detail for patient characteristics highlights a loss of valu-
able information on the potential effects of ethnicity and
consanguinity on prevalence. Also, it was generally un-
clear if the study population was representative of the
target population due to the issues surrounding under-
estimation and overestimation of patient numbers. This
is discussed further in study limitations. The STROBE
guidelines may not be the most suitable tool for asses-
sing the quality of prevalence studies in rare diseases as
they are designed to assess observational studies andoften the questions do not apply to such small popula-
tions, this is clearly an area for future research. There
are no checklists for the assessment of methodological
quality of rare disease studies. We have tried to account
for this using the fields in Tables 3, 4 and 5 relating to
consanguinity, ethnicity, study period, diagnosis and defin-
ition of prevalence. These fields allowed us to create a
judgement as to whether the reported prevalence is com-
promised and methodological quality should be explored
further in future research.
Study limitations
Overall the advancement and improvement of research
for rare diseases is hindered by lack of funding and lack
of samples. We have discussed that there are several areas
within the systematic review process that may limit the
current study (searching, screening and quality assess-
ment) however there are further limiting issues specific to
this study (prevalence definition and diagnosis).
There was a great deal of misunderstanding regarding
how prevalence data should be reported. Terms such as
incidence, prevalence, frequency and birth prevalence
were all used (some included either prenatal or postnatal
diagnoses or both) and often where calculations were
fully described it could be seen that the terms were used
interchangeably. As studies report different types of
prevalence we could not easily make comparisons, there-
fore we grouped together studies which reported similar
definitions using point prevalence or birth prevalence (in
agreement with the NBDPN guidelines). When analysing
birth prevalence studies rarely reported ‘diagnosis at
birth’. Classical presentation of Morquio A is usually diag-
nosed during early childhood; screening programmes for
rare diseases are impractical and expensive. In addition
since Morquio A is a recessive disorder the parents are
unaffected by the disease and so there is no obvious
reason to test at birth. However, for the purposes of this
review it was important to differentiate between those
studies which included cases ‘born during the study
period’ and ‘those diagnosed during the study period’ to
produce accurate birth prevalence calculations. The vast
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http://www.ojrd.com/content/9/1/173majority of studies that reported ‘prevalence’ actually re-
ported ‘birth prevalence’. In our review only one study
and three KOL reported point prevalence (prevalence at a
single point in time) [27-29,33]. We considered point
prevalence to be a more accurate measure of prevalence
than birth prevalence as it is not influenced by the length
of study period. Birth prevalence may not accurately
reflect the number of patients alive with the disease, since
there is the possibility that patients who are born within a
study may also die or migrate from a country during the
study period. The longer the period of the study the more
chance that either can happen; this effect does not in-
fluence point prevalence. Birth prevalence figures from
shorter study periods are more likely to reflect patients
alive than the longer study periods. The recent paper by
Lavery and Hendriksz 2014 indicated that 19% (5/27) of
patients with Morquio A in the UK had died before the
age of 10 [3]. To overcome these issues we also attempted
to estimate point prevalence from birth prevalence
(Table 6). These results are an average for the study period
and therefore do not provide a true reflection of current
Morquio A populations and are still open to all other
forms of bias.
Prevalence is clearly very dependent on accurate diag-
nosis and any review should consider how well this was
performed. To compare the prevalence of Morquio A
we stratified the results according to whether or not the
studies were diagnosed using the recommended enzyme
analysis in fibroblasts and leukocytes. Those using the
recommended analysis were considered to be of better
methodological quality. However, the technique of en-
zyme analysis is not perfect and can yield false negatives
when the enzyme is present at low quantities [10]. Low
levels of enzyme activity can also be found if the sample
has degraded during storage and therefore storage of
samples is an important point to consider especially in
studies performed over a long time period, consideration
of this is important as it may lead to an underestimation
of prevalence.
Underestimation of prevalence occurs if not all pa-
tients were included in the study and this may be due to
late diagnosis, mild forms of the disease and lack of
screening. Potential exists for over-estimation of preva-
lence. In studies with multiple sources of ascertainment
of data, it is possible, for a patient to be diagnosed at a
hospital and to exist as a member of a patient support
group. This may result in double counting of patients.
We have attempted to avoid double counting when we
retrieved multiple references for a given country but
it is difficult without detailed patient characteristics.
No studies reported any additional enzymatic testing
to rule out diseases such as MSD, MLII or MLIII as
recommended by Wood et al. 2013, so there is poten-
tial for mis-diagnosis and over-estimation of MorquioA patient numbers. Similarly, populations where consan-
guinity is typical and migration of ethnic groups where
Morquio A is more common will also result in above aver-
age prevalence of Morquio A. Often no distinction was
made between the sub-types. For some studies this may
reflect the use of data from pre-1976 (when the two dis-
eases were first identified) or it may also indicate the lack
of available accurate diagnostics test during a time period
or for a given region or lack of disease awareness.
Given the limitations discussed surrounding the report-
ing of prevalence data in this field we have made recom-
mendations to aid future research and hopefully produce
more accurate and comparable prevalence data on rare
diseases. Some recommendations may be already be sup-
ported by European Project for Rare Diseases National
Plans Development (EUROPLAN) [42].
Recommendations for systematic reviewers
 Development of a new set of reporting guidelines
and a quality assessment tool specific to rare
disease prevalence studies with specific emphasis
on 1) definition of disease, 2) method of diagnosis
and sample storage, 3) age at time of diagnosis,
4) ascertainment of data, 5) definition of prevalence,
and 6) suitability of measurement.
Recommendations for clinicians
 Use birth prevalence as defined by NBDPN
guidelines or point prevalence to record occurrence
of Morquio A in populations. Do not use prenatal
diagnoses unless live births result.
 A consensus should be reached on how to report
prevalence of rare diseases such as Morquio A
considering the challenges faced. With Morquio A
in particular, important points are 1) enzymatic
diagnosis, 2) defining and reporting type A and B
separately, 3) genetic analysis of patients, 4) clear
definition of point and/or prevalence 5) reporting
patient characteristics. This would make
comparisons possible across countries and provide a
more accurate assessment of the true prevalence of
Morquio A and similar conditions.
 An obligatory reporting or national registration
scheme should be set up for each country in order
to collate information on patients and provide access
to treatment.
Conclusions
Morquio A point prevalence was found to be 1 per
926,000, 1 per 599, 000; 1 per 1,872,000 in Australia,
UK and Malaysia respectively. In Denmark, point pre-
valence of unclassified Morquio was 1 per 323, 000. Birth
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http://www.ojrd.com/content/9/1/173prevalence for Morquio A ranged from 1 per 71,000 to 1,
179,000 across multiple countries. All results were com-
promised by poor study reporting and internal validity.
It is important to have an accurate reflection of the
prevalence of Morquio A in order to efficiently direct
treatment, funds and resources. Evidence of both over-
representation and under-representation of Morquio A
exists. Bespoke reporting guidelines, a quality assess-
ment tool specifically for prevalence of rare diseases and
agreed best diagnostic methods or screening programmes
would be a practical way to help clinicians produce
more meaningful data and allow comparison across
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